Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

General Updates | Phase III RISE UP trial updates and clinical implications: mitapivat in sickle cell disease

Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, discusses the results of the Phase III RISE UP trial (NCT05031780) of mitapivat, a pyruvate kinase activator, in sickle cell disease, which showed a significant hemoglobin response and reduction in hemolysis, but not a statistically significant reduction in pain crises. Dr Chakravorty suggests that mitapivat may be beneficial as an adjunct to hydroxyurea treatment and notes that its mechanism of action may potentially lead to long-term improvements in organ function. This interview took place virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.